RxDoctor Payments Data

Arthur Winer, MD

Medical Oncology · Fairfax, VANPI 1871939371

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,340 of the $10,404 with a category attached, or 89.8%. 5 manufacturers reported payments, led by AstraZeneca at 55.7% of the total.

$10,404in general payments, 2019–2025

Across 17 payments — averaging $611.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Gilead$4K
  • AbbVie$94
  • Astellas Pharma US Inc$93
  • GSK$67
$912,962in research payments, 2019–2025

Across 34 payments — averaging $26,852 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$436K
  • Mirati Therapeutics, Inc.$340K
  • Taiho Oncology, Inc.$89K
  • AstraZeneca$48K

What the payments were for

  • Consulting fees$9,34090%
  • Travel & lodging$5756%
  • Food & beverage$4214%
  • Education$671%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$5,792
Gilead9$4,358
AbbVie1$94
Astellas Pharma US Inc1$93
GSK1$67

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,404 in reported general payments places this provider in the 75th percentile of 95 medical oncology providers in Virginia.

See all medical oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$56,817
Medicare patients
167
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$34,054
EliquisApixaban32$21,326
Dexamethasone31$486
Ondansetron Hcl24$441
Pregabalin12$402
Oxycodone Hcl24$384
Doxycycline Hyclate15$330
Ondansetron OdtOndansetron11$301
Prochlorperazine Maleate22$261
Olanzapine23$256
Lidocaine-PrilocaineLidocaine/Prilocaine20$232
Gabapentin18$219
Hydrocortisone20$208
Pantoprazole Sodium14$156
Duloxetine Hcl14$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$94$34,05412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 95 medical oncology providers in Virginia.

Other medical oncology in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →